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Abstract
Purpose The secoiridoid oleuropein, as found in olives and olive leaves, modulates some biomarkers of diabetes risk in vivo. 
A possible mechanism may be to attenuate sugar digestion and absorption.
Methods We explored the potential of oleuropein, prepared from olive leaves in a water soluble form (OLE), to inhibit 
digestive enzymes (α-amylase, maltase, sucrase), and lower  [14C(U)]-glucose uptake in Xenopus oocytes expressing human 
GLUT2 and  [14C(U)]-glucose transport across differentiated Caco-2 cell monolayers. We conducted 7 separate crossover, 
controlled, randomised intervention studies on healthy volunteers (double-blinded and placebo-controlled for the OLE sup-
plement) to assess the effect of OLE on post-prandial blood glucose after consumption of bread, glucose or sucrose.
Results OLE inhibited intestinal maltase, human sucrase, glucose transport across Caco-2 monolayers, and uptake of glucose 
by GLUT2 in Xenopus oocytes, but was a weak inhibitor of human α-amylase. OLE, in capsules, in solution or as naturally 
present in olives, did not affect post-prandial glucose derived from bread, while OLE in solution attenuated post-prandial 
blood glucose after consumption of 25 g sucrose, but had no effect when consumed with 50 g of sucrose or glucose.
Conclusion The combined inhibition of sucrase activity and of glucose transport observed in vitro was sufficient to modify 
digestion of low doses of sucrose in healthy volunteers. In comparison, the weak inhibition of α-amylase by OLE was not 
enough to modify blood sugar when consumed with a starch-rich food, suggesting that a threshold potency is required for 
inhibition of digestive enzymes in order to translate into in vivo effects.
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Abbreviations
OLE  Olive leaf extract
IAUC  Incremental area under the curve
GLUT2  Solute carrier family 2, member 2 (SLC2A2)
GLUT5  Solute carrier family 2, member 5 (SLC2A5)
DMSO  Dimethyl sulfoxide
Introduction
Intervention and epidemiological studies have highlighted 
the importance of olives and olive oil in the Mediterranean 
diet. In the large intervention study “Predimed”, volunteers 
receiving a Mediterranean diet supplemented with extra-
virgin olive oil for 4.8 years relative to a control diet (with 
advice to reduce fat) exhibited a lower incidence of cardio-
vascular events [1]. Increased olive oil consumption was 
associated with a dose-dependent reduction in cardiovas-
cular disease mortality, with the highest quartile benefitting 
from a 44% reduction in risk [2]. In addition to the monoun-
saturated lipid components of olives and olive oil, one of the 
main biologically active substances is oleuropein (Fig. 1), 
which is found at high levels in olives (up to 70 mg/100 g), 
at much higher levels in unprocessed olives [3], and at lower 
levels in olive oil [4]. Oleuropein is also a major constituent 
of olive leaves, and “olive leaf extract” (OLE) is available as 
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a supplement, in which the main component is oleuropein. 
Numerous studies on rodents have shown that oleuropein has 
a beneficial effect on various factors related to diabetes and 
cardiovascular development [5–8]. In humans, a randomised, 
double-blind, placebo-controlled crossover single dose study 
showed that OLE significantly attenuated the digital vol-
ume pulse-stiffness index in healthy volunteers [9]. How-
ever, another randomised, double-blind, placebo-controlled 
crossover study using 500 mg OLE together with 100 mg 
green coffee bean extract and 150 mg beetroot powder for 
6 weeks showed no effect on blood pressure, blood lipids, 
glucose or insulin [10]. In a randomised placebo-controlled 
trial, adults with type 2 diabetes showed lowered HbA1c and 
fasting plasma insulin after 14 weeks of 500 mg OLE [11].
The mechanism by which oleuropein might affect diabe-
tes risk and development of related cardio-metabolic com-
plications is not clear. Since one of the suggested actions of 
green tea polyphenols against diabetes is to improve glu-
cose homeostasis [12] and attenuate post-prandial glucose 
absorption and metabolism [13, 14], we explored the pos-
sibility that oleuropein could work at least in part in a similar 
way, by attenuating carbohydrate digestion. Preliminary evi-
dence has shown that oleuropein might inhibit α-glucosidase 
activities. However, some of the conducted studies used the 
enzyme from yeast (Saccharomyces cerevisiae), which has 
very little homology to the target human enzyme, and shows 
a completely different profile of inhibition. For example, the 
drug acarbose inhibited rat and human maltase activities 
with  IC50 of 0.42 and 5.7 μM respectively [15], but inhib-
ited yeast α-glucosidase activity much less effectively with 
 IC50 ~ 250 μM [16]. When using the yeast enzyme, hydrox-
ytyrosol and oleuropein both showed inhibition [16], and 
some extracts from olive oil also inhibited the yeast enzyme 
[17]. For porcine α-amylase, oleuropein and hydroxytyrosol 
were both weak inhibitors [16]. When a large dose of OLE 
was given to healthy volunteers together with a large dose of 
rice, there was no difference in postprandial blood glucose 
in healthy volunteers, but a decrease was observed in “bor-
derline” volunteers (although “borderline” was not defined). 
The authors ascribed these changes to inhibition of human 
salivary and pancreatic α-amylase by luteolin glucoside and 
oleanolic acid [18]. As the results in the literature are mixed, 
with very little information on inhibition of human enzymes 
which constitute the most relevant in vitro system, we have 
evaluated the effect of OLE on both carbohydrate digestion 
enzymes and sugar transporters in vitro, and demonstrated 
how these mechanisms translate into modulation of post-
prandial glucose in vivo in healthy volunteers consuming 
different types of carbohydrate.
Materials and methods
Materials
OLE in the form of capsules  (Bonolive®,  Olecol®) and as 
powder was obtained from BioActor B.V. (Maastricht, The 
Netherlands). d-Glucose and d-fructose were obtained from 
Fisher Scientific (Loughborough, UK). Acetone-protein 
extract from rat intestine, pancreatin from porcine pancreas, 
pepsin, Dulbeccos’s modified Eagle’s Medium (DMEM), 
foetal bovine serum (FBS), glucose and sucrose for in vitro 
studies, non-essential amino acids, penicillin/streptomycin 
solution, trypsin, hexokinase reagent, potassium oxalate/
sodium fluoride tubes, acarbose, oleuropein (> 98%), dime-
thyl sulfoxide (DMSO), amylose from potatoes, maltose and 
chromatographically purified human salivary α-amylase type 
IX-A were purchased from Sigma–Aldrich (Dorset, UK). 
Caco-2/TC7 cells were a kind gift from Dr M. Rousset, 
(U178 INSERM, Villejuif, France). D-[14C(U)]-glucose was 
from Perkin Elmer (Boston, USA) and D-[14C(U)]-fructose 
was from Hartmann Analytic (Braunschweig, Germany). 
Milli-Q water was used to make up all laboratory solutions 
(Millipore, Watford, UK). Glucose powder for human stud-
ies was purchased from Greens Pharmacy (Amazon, UK), 
and sucrose for consumption was purchased from a local 
supermarket. Bread was 109 g Warburtons™ medium sliced 
Fig. 1  Chemical structures. Structure of oleuropein (IUPAC 
name: methyl (4S,5E,6S)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-
2-oxoethyl]-5-ethylidene-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-
6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate) 
and “oleuropein aglycone” (IUPAC name: methyl (4S,5E,6R)-
4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-5-ethylidene-6-hy-
droxy-4H-pyran-3-carboxylate)
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white bread that contained 50 g of available carbohydrate 
[19]. Accu-Chek Aviva (Roche Scientific) glucometers and 
test strips were obtained from Boots (Nottingham, UK). 
Accu-Chek glucose control solutions were obtained from 
Weldricks Pharmacy (Doncaster, UK).
Analysis of oleuropein in olives and in supplements
Samples were analysed for oleuropein content using an Agi-
lent Technologies 1200 series HPLC with diode array detec-
tion and a ZORBAX Eclipse plus C18 column (2.1 mm × 
100 mm, 1.8 μm; Agilent Technologies) kept at 35 °C. The 
injection volume was 5 μl. Separation was achieved on a 
gradient of solvent A (0.2% acetic acid, 99.8% water) and 
solvent B (acetonitrile) at a flow rate of 0.25 ml/min, starting 
at 10% B and at 9 min 35% B, at 10 min 100% B until 13 min 
and returning at 14 min to 10% B. For quantitation of oleuro-
pein, an external standard curve was constructed. Oleuropein 
was dissolved in 100% DMSO (40 mM) and diluted in the 
starting conditions of the chromatographic gradient (10% 
acetonitrile, 0.2% acetic acid, 89.8% water).
For analysis of the OLE samples, 2.5 mg of powder was 
dissolved in 4 ml water, and the solution filtered through a 
0.2 μm PTFE filter. Samples were analysed three times in 
duplicate. For analysis of olives, ~ 2.5 g of olives were cut 
into small pieces and homogenised with 3 ml of 80% metha-
nol. The solution was centrifuged, the pellet re-extracted 
with an additional 3 ml methanol, the supernatants pooled 
and filtered through a 0.2 μm PTFE filter. Olive samples 
were also spiked with different amounts of oleuropein at the 
homogenisation stage to calculate the extraction efficiency, 
which was 72 ± 6%. The oleuropein content in olives is 
shown in Table 1.
Bonolive® is a standardised water soluble extract pre-
pared from the cut leaves of Olea europaea L. (the common 
olive tree), and has been used in previous interventions, such 
as Filip et al., where it was safely fed to volunteers for 12 
months [20]. The total phenolic content of  Bonolive® was 
50%, and included inert excipients added for encapsulation. 
Of the phenolic content, oleuropein constituted ~ 80%, equiv-
alent to 40% content of oleuropein with no other phenolic 
compounds exceeding ~ 3%. The studies reported here were 
on OLE in the form of  Bonolive®, apart from intervention 
studies 1 and 2 on OLE in capsules which were performed 
on  Olecol®, which is also water-soluble, and had an oleuro-
pein content of ~ 50% of that of  Bonolive® (Table 1).
Hydrolysis and stability of oleuropein
Enzyme solutions were prepared by addition of 300 mg of 
porcine pancreatin, acetone extract of rat intestine, or hes-
peridinase to 12 ml sodium phosphate buffer (pH 6). OLE 
(4.58 mg/ ml) and quercetin-3-O-glucoside (0.1 mM) were 
dissolved in water. After incubation for the indicated time 
under the specified conditions, reactions were stopped by 
placing in a boiling water bath for 5 min, followed by 2 min 
on ice, before 1.1 ml acetonitrile and 9.1 ml water were 
added and the samples filtered through a 0.2 μm PTFE filter 
for analysis by HPLC. The final protein concentration in the 
oleuropein enzymic solution was: 0.079 mg/ml for pancrea-
tin, 0.124 mg/ml for the rat intestinal extract and 0.0013 mg/
ml for hesperidinase. For quercetin-3-O-glucoside, enzymic 
solutions were 0.091, 0.141 and 0.0015 mg/ml respectively. 
Quercetin-3-O-glucoside was analysed using the same gradi-
ent as described above using an external calibration curve.
Measurement of human salivary α‑amylase activity
Inhibition of α-amylase was measured as described previ-
ously, using human salivary α-amylase with an optimised 
protocol [21].
Measurement of maltase and sucrase activities
Inhibition of sucrase and maltase was tested using a protein 
extract of rat intestine and Caco-2/TC7 cells as the enzyme 
source (cultured as described below) according to a previ-
ously optimized protocol, using sucrose and maltose as sub-
strates respectively [15]. Where indicated, oleuropein was 
removed by SPE prior to glucose quantification [15].
Purification of maltase from rat intestine
A protein extract from rat intestine was prepared freshly 
before use by acetone precipitation, and used as the enzy-
mic source of α-glucosidase. The powdered extract (30 mg) 
was added to 1 ml of water, vortexed for 10 s, centrifuged 
(15 min, 10,000×g, 4 °C) and the supernatant collected. 
Papain (in 0.012 M EDTA, 0.012 M cysteine, 0.024 M 
potassium phosphate buffer) was added to the acetone pow-
der (0.1% w/w) to remove the enzyme from its membrane 
attachment [22]. Following incubation for 30 min at 37 °C 
the sample was placed on ice and centrifuged (105,000g, 
4 °C) for 60 min. Papain addition increased the apparent 
Table 1  Composition of OLE preparations and olives used in these 
studies
Data are mean and standard deviation of n = 3 determinations
1 Bonolive® powder also contained tyrosol (0.045% w/w) and hydrox-
ytyrosol (0.0065% w/w) as estimated by HPLC (see “Materials and 
methods”)
Oleuropein content
Bonolive®  powder1 41.8 ± 0.9% w/w
Olecol® powder 19.8 ± 0.5% w/w
Kalamata olives 34.8 ± 0.4 mg oleuropein/100 g
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total enzyme activity by ~ 36%. Enzyme purification was 
carried out with an ÄKTA Purifier System (GE Healthcare, 
Fairfield, CT, USA) controlled by a PC running GE Uni-
corn software (5.11). The papain-treated product (1 ml) was 
loaded manually using a syringe and a sample loop of 0.1 ml 
on a Q Sepharose Fast Flow XK 16/40 column (GE Health-
care, USA) and eluted with a gradient of sodium phosphate 
buffer (10 mM, pH 7, Solvent A) and 0.2 M KCl (Solvent 
B) at a flow rate of 0.2 ml/min. The elution was followed at 
280 nm. Maltase eluted at the beginning of the KCl gradi-
ent and fractions were collected with a Frac-900 fraction 
collector in 18 ml tubes. Fractions from multiple runs were 
pooled and freeze dried to obtain sufficient enzyme for the 
inhibition assays. The procedure resulted in a 2300-fold 
purer enzyme based on specific maltase activity.
Cell culture
Caco-2/TC7 cells were cultured in DMEM (25 mM glucose) 
supplemented with 20% (v/v) foetal bovine serum, 2% (v/v) 
Glutamax (Invitrogen, Thermo Fisher Scientific, UK), 2% 
(v/v) non-essential amino acids, 100 U/mL of penicillin and 
0.1 mg/mL streptomycin. Cells were seeded at a density of 
1.2 × 106 cells per 75 cm2 culture flask (37 °C, 10%  CO2). 
For enzyme assays, cells allowed to differentiate for 21–23 
days were scraped and pellets were snap frozen in a dry ice-
ethanol bath and kept at − 80 °C.
Sucrose transport across differentiated Caco‑2/TC7 
cell monolayers
Cells were cultured on Transwell plates (Corning 3412, 
Appleton Woods, UK) as previously described [14]. Caco-2/
TC7 cells were incubated with 1, 5 or 25 mM sucrose added 
in the apical compartment for 60 min and the concentration 
of glucose and fructose were measured in the apical and 
basolateral solutions. OLE (in the form of powder extract 
 Bonolive®) was added to the apical solution at 0.5, 1.5, 
or 3.0 mg/mL resulting in 0.2, 0.6, 1.2 mg oleuropein/ml 
respectively.
High performance anion exchange chromatography 
with pulsed amperometric detection (HPAE‑PAD)
Analysis of sugars was conducted on an ICS-4000 ion cap-
illary system equipped with a pulsed amperometric detec-
tor (PAD), an electrolytic eluent generator to automatically 
produce an isocratic potassium hydroxide eluent and an 
AS-AP autosampler (Dionex, Thermo Fisher Scientific, 
Hemel Hempstead, UK). Instrument control, data collec-
tion and processing was carried out through a Chrome-
leon software (version 7.2 SR4, Thermo Fisher Scientific, 
UK). A palladium reference electrode and a gold working 
electrode were used with a collection rate of 2.00 Hz using 
the “Gold, Carbo, Quad” waveform. Separation of sugars 
was achieved at a flow rate of 0.008 ml/min on a Carbopac 
PA20 column (0.4 × 150 mm) attached to a CarboPac PA20 
Guard (0.4 × 35 mm) (Thermo Fisher Scientific, UK) kept 
at 30 °C (0.04 µl injection volume). Quantitation of sugars 
was based on an external calibration curve as previously 
described [15]. Apical and basolateral samples from trans-
port studies were diluted fivefold with Milli-Q water; the 
limit of quantification of glucose and fructose was 1 μM, 
and so samples with a concentration > 5 μM could be quanti-
fied. The presence of OLE in the apical solutions interfered 
with measurements of sugars and therefore separate standard 
curves were constructed incorporating final concentrations 
of 0.04, 0.12 and 0.24 mg oleuropein/ml. All standards and 
samples were filtered with 0.2 µM PTFE filters and kept at 
4 °C in the autosampler until analysis.
Glucose transport across differentiated Caco‑2/TC7 
cell monolayers
Glucose transport was assessed in Caco-2/TC7 fully differ-
entiated cell monolayers cultured and maintained for experi-
ments as previously described on Transwell plates (Corn-
ing 3412, Appleton Woods, UK) for 23 days [14]. For the 
glucose transport assay from the apical to the basolateral 
side,  [14C(U)]-glucose (0.1 μCi/ well) was added to the api-
cal compartment in transport buffer (TBS, 20 mM HEPES, 
137 mM NaCl, 4.7 mM KCl, 1.8 mM  CaCl2) containing 
either 2, 5, 11 or 25 mM glucose. OLE (in the form of pow-
der extract  Bonolive®) was prepared in TBS. For transport 
experiments in the absence of sodium (− Na+), TBS was 
prepared only with KCl. Cell monolayers were incubated 
for 30 min (37 °C, 5%  CO2) and solutions from both apical 
and basolateral compartments were collected for scintillation 
counting as described before [14].
Inhibition of transport by GLUT2 and GLUT5 
expressed in Xenopus oocytes
GLUT2 and GLUT5 were expressed in Xenopus oocytes and 
 [14C(U)]-glucose and  [14C(U)]-fructose sugar uptake experi-
ments were performed as previously described [14].
Characterisation of OLE capsule dissolution 
under gastrointestinal conditions
In order to mimic the conditions in the stomach, pepsin 
(3 ml of 1.6 g pepsin powder in 10 ml of 0.1 M HCl) was 
added to 150 ml water and the pH adjusted to 2.0 using 
HCl (0.1 M). One OLE capsule  (Olecol®) was added to the 
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pepsin solution with continuous stirring at 37 °C and dis-
solution was observed visually.
Intervention studies on healthy volunteers
All intervention studies were approved by the University 
of Leeds, Faculties of Mathematics and Physical Sciences 
and Engineering Ethics Committee (MEEC), were registered 
at clinicaltrials.gov (approval numbers and clinicaltrials.
gov reference numbers shown in Table 2) and were con-
ducted between July 2015 and August 2017. A pre-study 
questionnaire was used to assess the suitability of partici-
pants for the studies. The inclusion criteria were apparently 
healthy, aged between 18 and 75 years old, not smoking, 
not diabetic, not on long term prescribed medication, not 
allergic to olives, not pregnant, not lactating and not on any 
special diets including weight loss diets or fruit supple-
ments, with fasting blood glucose between 3.9 and 5.9 mM. 
Written informed consent was provided by all participants 
before the commencement of the study. Height and weight 
of volunteers was recorded at the beginning of the study 
and subjects received the treatments in a cross-over design 
in randomised order. Control samples were consumed as 
indicated per study, but the nature of the test food meant 
that only some studies could be double-blinded as described 
below. During the studies, participants consumed their nor-
mal diet, but were instructed to eat the same evening meal 
the day before each visit. Participants were asked to arrive 
at the School of Food Science and Nutrition in the morning 
around 9.00 am after an overnight fast of 10–12 h. Each 
participant was assigned a code and all data were stored 
anonymised. Each visit lasted ~ 3 h and capillary blood sam-
ples were obtained by finger prick at 0 min (fasting blood 
glucose) using an Accu-Chek Aviva glucometer according to 
the FAO/WHO approved method [23]. The accuracy of the 
glucometer was tested using control solutions; three separate 
readings of a 2.5 and a 16.5 mM glucose solution gave 2.5, 
2.4 and 2.4 mM; and 16.5, 16.3 and 16.3 mM respectively. 
Glucometer readings were not significantly different when 
compared to measurements with the hexokinase-linked assay 
on the same blood samples (data not shown).
Volunteers were calm for several minutes before meas-
urements, with the hand palm-side up, and after using a 
sterile wipe to clean the fingertip, a new lancet was used 
to puncture the centre of the fingertip with mild pressure to 
aid blood flow. The first drop of blood was discarded using 
a cotton swab, and the second drop was used for measure-
ments, which were taken at nine time points—0, 15, 30, 
45, 60, 90, 120, 150 and 180 min, and the data used to plot 
a glucose response curve. The incremental area under the 
curve (IAUC) was used as the main indicator of changes in 
glucose response between interventions, and this analysis is 
reported to be the best method for this type of study [24]. 
Full details have been described previously [25].
Specific aspects of the protocol followed for study 1 
and 2 on OLE in capsules
Studies with OLE capsules were randomised (Latin square 
design), double-blinded and placebo controlled. Both study 
scientists and participants were blinded to the treatment 
until the end of the study. Participants (n = 24) consumed 
either a placebo (a capsule containing 500 mg cellulose) or 
a low dose of OLE (one capsule containing 500 mg of OLE, 
equivalent to 100 mg oleuropein) or twice the same dose of 
OLE (two capsules totalling 1000 mg of OLE, equivalent 
to 200 mg oleuropein). The OLE used in the capsules was 
 Olecol®. Five minutes after the capsules were consumed, 
participants were given 109  g of Warburton’s Medium 
White bread, containing 50 g of available carbohydrates 
[19]. Timing began when the participant took the first bite 
of bread, and the time taken to eat the bread was recorded. 
Each participant was given a total of 250 ml water with each 
intervention.
Specific aspects of the protocol followed for study 3 
on olives
Sixteen volunteers were recruited. All study participants 
consumed the test meal (109 g white bread) with or without 
100 g olives (Greek Kalamata black olives, Sainsbury’s, UK) 
in a randomised, crossover design. Olives were de-pitted, cut 
finely and spread onto the bread, and both test meal and 
control were consumed with water (200 mL). Participants 
attended twice for each treatment.
Specific aspects of the protocol followed for studies 
4–8
Each study was randomised with a crossover design. Ten 
healthy participants were recruited for each study and each 
attended four visits (two visits per treatment). For studies 
4–7, 125 mg of OLE (equivalent to 50 mg oleuropein) was 
dissolved in 200 ml of water; and for study 8, 0.4 g of OLE 
(equivalent to 160 mg oleuropein) was dissolved in 250 ml 
of water (Table 2). Participants consumed the test and con-
trol meals in a randomised order and blood samples were 
collected starting after the first bite or sip. For study 5, Hovis 
Medium Wholemeal Loaf (800 g) was purchased from the 
local supermarket and provided 37.8 g carbohydrate per 
100 g.
 European Journal of Nutrition
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Statistics and replicates
Intervention studies were carried out with a minimum of 
10 participants, which is the recommended minimum num-
ber for these types of determinations [23]. For the study on 
olives, the trial was designed to have 90% power to detect a 
clinical difference of 15% IAUC between the test and refer-
ence meal (α = 0.05), where a minimum of 15 volunteers 
were required for the reference and test meals to achieve the 
above power and clinical difference. The trapezoidal rule 
was used to calculate the incremental area under the glu-
cose curves (IAUC) for each volunteer, and data analysis 
was performed by the two-tailed paired t test. Comparisons 
between control and treatment in  [14C(U)]-glucose transport 
experiments were carried out by the two-tailed independent 
samples t test and data are presented as mean ± SD with 
a minimum of 3 independent experiments and 6 replicates 
well/experiment. For  [14C(U)]-glucose and  [14C(U)]-fructose 
uptake experiments into Xenopus oocytes expressing human 
GLUT2 and GLUT5, data were normalized against water-
injected oocytes for each condition, and the two-tailed inde-
pendent samples t test was used to assess significance.
For sucrase and maltase assays, the percentage inhibi-
tion was determined by the following formula: % inhibi-
tion = [([Glucose]Control-[Glucose]inhibitor)/[Glucose]control] 
× 100, where the control is without inhibitor. Statistics 
were performed by one-way ANOVA using SPSS Statis-
tics version 24 and statistical significance was determined 
by Tukey–Kramer multiple comparison test (p ≤ 0.05). The 
data are presented as mean ± SEM with minimum of n = 3. 
Cell lysates were prepared from three biological passages of 
cells and used for  IC50 determinations. For transport studies, 
results were normalised to the control and one-way ANOVA 
performed with statistical significance determined by the 
Tukey–Kramer multiple comparison test (p ≤ 0.05). Three 
independent transport experiments were performed with 
three biological passages of cells with six technical repli-
cates for each experiment.
Results
OLE composition and stability
The olive leaf extract (OLE) tested throughout the studies 
presented here provided a convenient source of oleuro-
pein in a formulation with enhanced solubility, suitable for 
both in vitro experiments and in vivo intervention studies. 
The two preparations used were characterised by HLPC 
(Table 1). The bioactivities tested here mostly take place 
in vivo in the gut lumen and intestinal tissues. Once ingested, 
food components are subjected to digestive enzymes and 
the pH conditions prevailing in the different sections of 
the gut lumen. To test if oleuropein would be hydrolysed 
by digestive enzymes, we carried out in vitro incubations. 
Neither pancreatic enzymes nor a protein extract from rat 
intestine hydrolysed oleuropein over an extended period of 
time (Fig. 2a). As a positive control, we showed that querce-
tin-3-O-glucoside was hydrolysed by the intestinal extract 
(owing to its content of β-glucosidases [26]) but not by the 
pancreatic extract, as expected. Under our conditions, both 
oleuropein and quercetin-3-O-glucoside were hydrolysed 
by the fungal hemicellulase (“hesperidinase” from A. niger) 
preparation [27], but this enzyme is not present in the small 
intestine. The results imply that oleuropein would exist in 
the small intestine in its intact form, and could potentially 
interact with digestive enzymes and transporters.
Effect of OLE on human salivary α‑amylase
OLE inhibited human salivary α-amylase, and the extent 
of inhibition depended on the substrate (Fig. 2b). When 
amylopectin was used as substrate, oleuropein showed 
almost no inhibition, while with amylose the  IC50 value was 
~ 0.8 mg/ml (Fig. 2b; Table 3). Acarbose, as expected, was 
a potent inhibitor of α-amylase, but in combination with 
OLE, an additive effect was evident, however no synergy 
was observed (Fig. 2c).
Effect of OLE on α‑glucosidase activities
OLE inhibited rat intestinal maltase activity (Fig. 3a). Since 
maltase activity can arise both from maltase-glucoamylase 
and sucrase-isomaltase enzymes, and the presence of other 
proteins in the intestinal extract could potentially affect the 
inhibition, we purified the main maltase activity from rat 
intestine. Papain digestion was used to free the enzyme 
from the brush border of the enterocytes, and this treatment 
resulted in an apparent 36% increase in activity. The enzyme 
was purified 2300-fold. Only a small amount of enzyme was 
obtained, and although the error in measurements is conse-
quently higher, the inhibition by OLE of the crude and puri-
fied enzyme were not significantly different (t- test, 0.816, 
p > 0.05) (Fig. 3b). This indicates that other proteins present 
in the intestinal extract do not interfere with the estimation 
of inhibition. OLE also inhibited human maltase activity 
(Fig. 3c), with an  IC50 value (Table 3) ~ twofold higher than 
that obtained for rat maltase.
OLE inhibited only weakly rat sucrase activity when 
tested up to a concentration of 2  mg oleuropein/ml 
(36.8 ± 1.6% inhibition). Sucrase activity in both rats and 
humans arises from a single enzyme, sucrase-isomaltase; 
a brush border enzyme which consists of two subunits. In 
comparison, OLE inhibited human sucrase activity dose-
dependently (Fig. 3d) allowing an  IC50 value to be estimated 
(Table 3).
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The phenolic component of the OLE preparation used 
in vitro contains only extremely low levels of tyrosol and 
hydroxytyrosol. To ensure that these phenolics did not con-
tribute to the observed inhibition we determined their content 
by HPLC (Table 1). Since the hydroxytyrosol concentration 
required to inhibit rat sucrase by 50% (i.e.  IC50 value) was 
0.0925 mg/ml, and the content of hydroxytyrosol in a 2 mg/
ml  Bonolive® solution (0.8 mg oleuropein/ml) is 0.00013 mg/
ml, we can safely conclude that the concentration of hydroxy-
tyrosol is too low to contribute significantly to the observed 
inhibition. Likewise, rat maltase inhibition by hydroxytyrosol 
reached 9.7% at the highest concentration tested, 0.154 mg/ml 
(1 mM), which is much higher than the 0.00013 mg/ml present 
in a 2 mg/ml  Bonolive® solution. Tyrosol neither inhibited 
rat maltase nor sucrase at the highest concentration tested of 
0.138 mg/ml (1 mM). The inhibitory activities reported here 
can therefore be confidently attributed to oleuropein, which 
constitutes > 80% of the phenolic composition.
Oleuropein (mg/ml)
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Fig. 2  Stability of OLE and interaction with human salivary 
α-amylase. a Enzymatic hydrolysis of oleuropein as assessed using 
HPLC with diode array detection (see “Materials and methods”). 
Oleuropein was incubated at 37  °C with porcine pancreatin (79 μg 
protein/ml) (dark grey bars), a protein extract from rat intestine (124 
μg protein/ml) (grey bars), or “hesperidinase” from A. niger (1.3 μg 
protein/ml) (light grey bars), in 0.05 M sodium phosphate buffer pH 
6. Black bars indicate oleuropein with no added enzymes. Under 
similar conditions, quercetin-3-O-glucoside (100 μM), as control, was 
rapidly hydrolysed by the rat intestinal preparation (~ 30% remaining 
at 3 h, none detectable at 6 h) and by hesperidinase (~ 40% remain-
ing after 6 h, none detectable at 70 h). Quercetin-3-O-glucoside was 
unaffected by pancreatin. b Inhibition of human salivary α-amylase 
using either amylose (black triangle) or amylopectin (black circle) as 
substrate, and measuring product using 2,4-dinitroasalicylic acid. c 
Effect of combining oleuropein with acarbose on inhibition of human 
salivary α-amylase. Black bars show OLE alone, dark grey bars show 
acarbose and the light grey bars show a combination: Treatment num-
ber 1: OLE (oleuropein, 0.8 mg/ml), acarbose, 2.5 µM; 2: OLE (ole-
uropein, 0.6 mg/ml), acarbose, 1.88 µM; 3: OLE (oleuropein, 0.4 mg/
ml), acarbose, 1.25 µM. *p ≤ 0.05, **p ≤ 0.01
Table 3  Inhibition of digestive 
enzymes by OLE
Data are mean ± SD (n = 3)
a Amylopectin as substrate at 0.37 mg/ml
b Amylose as substrate at 1.0 mg/ml
c Values in mg oleuropein /ml
d ND = inhibition did not reach 50% at concentrations up to 2 mg oleuropein/ml
Human α-amylasea Human α-amylaseb Rat maltase Human maltase Rat sucrase Human sucrase
IC10 (mg/ml)c IC50 (mg/ml)c
0.8 ± 0.2 0.8 ± 0.1 0.24 ± 0.08 0.52 ± 0.08 NDd 1.28 ± 0.4
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Effect of OLE on  [14C(U)]‑glucose transport 
across differentiated human Caco‑2 cell monolayers
OLE dose-dependent ly  inhibi ted  t ranspor t  of 
 [14C(U)]-glucose across differentiated Caco-2/TC7 cell 
monolayers (Fig. 4a), with  IC50 ~ 0.5 mg oleuropein/ml. 
The inhibition of transport was observed over a range 
of glucose concentrations (2.5–25 mM) and was unaf-
fected by the absence of sodium in the transport buffers 
(Fig. 4b).
Effect of OLE on  [14C(U)]‑glucose and fructose 
transport into Xenopus oocytes expressing human 
GLUT2 or GLUT5
The lack of effect of sodium on inhibition by oleuro-
pein suggested that GLUT transporters, and not sodium-
dependent SGLT1, are the targets of oleuropein inhibition. 
We therefore determined if oleuropein could inhibit 
GLUT2 or GLUT5 expressed in Xenopus oocytes. OLE 
dose-dependently inhibited  [14C(U)]-glucose transport by 
GLUT2 (Fig. 4c), but had no effect on  [14C(U)]-fructose 
transport by GLUT5 (Fig. 4d).
Effect of OLE on sucrose hydrolysis and transport 
by differentiated human Caco‑2/TC7 cell monolayers
To determine the fate of the sugars derived from sucrose 
hydrolysis and their subsequent transport we used a chro-
matographic method to detect and quantify sucrose, glu-
cose and fructose (Fig. 5a–c). When sucrose was added to 
the apical side of differentiated Caco-2/TC7 differentiated 
cell monolayers, it was hydrolysed by sucrase on the brush 
border on the apical side of the cells into glucose and fruc-
tose in a concentration dependent manner (Fig. 5d). These 
sugars can then be absorbed by the cells and either used 
for energy, or transported to the basolateral compartment, 
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Fig. 3  Inhibition of α-glucosidases by OLE. a Inhibition of rat intes-
tinal maltase activity, using maltose (4 mM) as substrate, and quan-
tifying glucose produced using a hexokinase-linked assay. b Inhibi-
tion of crude and purified rat intestinal maltase by OLE. Crude rat 
intestinal preparation (grey bars) and 2300-fold purified preparation 
of rat maltase (black bars) were incubated with maltose and inhibi-
tor as described in the experimental section. The  IC50 values for 
OLE inhibition were not significantly different (0.46 ± 0.14 and 0.40 
± 0.26 mg/ml of oleuropein respectively). c, d Inhibition of human 
maltase and sucrase activity using Caco-2/TC7 cells as the enzyme 
source. Glucose was quantified using a hexokinase-linked assay after 
the removal of interfering compounds by SPE. The  IC50 values for 
maltase and sucrase were 1.28 ± 0.4 and 3.2 ± 1.0 mg/mL oleuro-
pein, respectively
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and this led to the appearance of glucose in the basolateral 
compartment. Fructose was, however, below the limit of 
detection under these experimental conditions (concentra-
tion < 5 μM) (Fig. 5d). Addition of OLE to the apical com-
partment dose-dependently inhibited this process (Fig. 5e), 
owing to both inhibition of sucrase activity and of glucose 
transport (as shown in Figs. 3, 4).
Effect of OLE on post‑prandial glucose 
following consumption of bread by healthy 
volunteers (studies 1–5)
We performed intervention studies on young, apparently 
healthy volunteers who consumed OLE in capsules or in 
solution together with bread (equivalent to 50 g available 
carbohydrate). In preliminary experiments, under condi-
tions mimicking the stomach, the capsules released their 
contents within 3  min, and were completely dissolved 
within 5 min. Table 2 summarises the details of the inter-
vention studies that were conducted. Post-prandial blood 
glucose was measured and the data is presented in Fig. 6. 
Consumption of OLE in capsules with white bread did not 
affect the post-prandial blood glucose concentrations over 
a 3 h period. Consumption of olives, or of OLE in solution, 
with white bread similarly produced no changes in blood 
glucose, and the effect was not changed if wholemeal bread 
was consumed.
Effect of OLE on post‑prandial glucose 
following consumption of sugars by healthy 
volunteers (studies 6–8)
We performed intervention studies on young, apparently 
healthy volunteers who consumed OLE in solution together 
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Fig. 4  Effect of OLE on sugar transport. a Concentration dependence 
of OLE on transport of  [14C(U)]-glucose (5  mM) across differenti-
ated Caco-2/TC7 cell monolayers. ***p ≤ 0.001, compared to control 
with no OLE (n = 3 separate experiment with 6 replicates each). Error 
bars represent SD. b Effect of OLE (0.4 mg oleuropein /ml) on trans-
port of  [14C(U)]-glucose (5  mM) across differentiated Caco-2/TC7 
cell monolayers at different apical  [14C(U)]-glucose concentrations 
(n = 3 biological replicates with n = 6 wells per biological replicate; 
black bars). Error bars represent SD. **p ≤ 0.01, ***p ≤ 0.001 com-
pared to control (grey bars) with no OLE. c Effect of OLE on glucose 
uptake by Xenopus oocytes expressing GLUT2. Two days post-cRNA 
microinjection, oocytes were incubated in 0.1 mM  [14C(U)]-glucose 
with OLE for 5 min. Each data point represents the mean ± SEM of 
twelve replicates;  IC50 = 0.012 ± 0.001  mg/ml. *p ≤ 0.05. d Effect of 
OLE on glucose uptake by Xenopus oocytes expressing GLUT5. One 
day post-cRNA microinjection, oocytes were incubated in 0.1  mM 
 [14C(U)]-fructose with OLE for 5 min. Each data point represents the 
mean ± SEM of six replicates (18 oocytes)
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with glucose or sucrose (Table 2). Post-prandial glucose was 
measured and resulting curves are shown in Fig. 7. At the 
lower dose of sucrose and higher dose of OLE, a highly sig-
nificant decrease (p < 0.0002) in peak glucose was observed 
in all individuals (Fig. 8). There was also a significant 
decrease in IAUC with OLE consumption (p = 0.025). When 
the dose of OLE was lower and given with 50 g glucose or 
sucrose, no significant effect was observed on post-prandial 
blood glucose. The changes in all intervention studies are 
summarised in Fig. 9.
Discussion
Studies on rodents have shown effects of oleuropein on 
glucose metabolism and diabetes risk. For example, ole-
uropein (intraperitoneal, 5 mg/kg) significantly decreased 
serum glucose in streptozotocin-induced diabetic rats [28], 
and oral oleuropein attenuated hyperglycaemia and impaired 
glucose tolerance in the type 2 diabetes model Tsumura 
Suzuki Obese Diabetes mice with no effect on obesity [6]. 
In diabetic-hypertensive male Sprague–Dawley rats receiv-
ing oleuropein (20, 40, or 60 mg/kg/day), blood pressure 
and blood glucose, as well as infarct size, were significantly 
improved [29]. In C57BL/6 mice fed a 60% high-fat diet to 
generate non-alcoholic steatohepatitis, oleuropein (0.05% 
diet) over 6 months improved HOMA-IR and leptin levels 
[8], while serum glucose and cholesterol levels in alloxan-
induced diabetic rats were decreased by oleuropein (8 and 
16 mg/kg body weight) after 4 weeks [30]. In humans, OLE 
attenuated the digital volume pulse-stiffness index [9], and 
lowered HbA1c and fasting plasma insulin [11], but was not 
effective against oxidative damage markers [31] nor when 
combined with green coffee bean extract and beetroot pow-
der [10].
Several mechanisms could contribute to the protective 
effect(s) of dietary oleuropein [32, 33]. One mechanism to 
lower risk of developing type 2 diabetes is by consumption 
Fig. 5  Effect of OLE on sucrose hydrolysis. a Representative trace of 
separation of glucose, fructose and sucrose at 5 μM (0.04 μl loaded; 
0.2 pmol each loaded onto the column) on a Carbopac PA20 column 
at 0.008 ml/min by HPAE-PAD on an ICS-4000 system. b, c Stand-
ard curves used for quantification of glucose and fructose respectively 
in the presence of final concentrations of 0 (black square), 0.04 (black 
circle), 0.12 (black triangle) or 0.24 (cross symbol) mg oleuropein/
mL. d Transport experiments in Caco-2/TC7 cells. After incubation 
with 1, 5 or 25 mM sucrose (60 min) in the apical compartment, api-
cal fructose (black), apical glucose (grey) and basolateral glucose 
(white) were quantified by HPAE-PAD. Basolateral fructose con-
centration was < 5  µM within the timeframe of the experiment. e 
Concentration-dependence of OLE on sucrose hydrolysis and glucose 
transport by differentiated Caco-2/TC7 cell monolayers after incu-
bation with 5 mM sucrose (60 min). Apical glucose (black square), 
basolateral glucose (black square) and apical fructose (black triangle) 
were quantified. Results are means ± SEM, transport experiments 
were performed with n = 3 biological replicates with n = 6 wells per 
biological replicate. ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05
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of low glycaemic index foods [34], which have signifi-
cant health benefits when compared to diets rich in rap-
idly absorbable sugars [34]. Polyphenols may reduce post-
prandial glycaemia [35], while any food components able 
to slow down carbohydrate digestion and glucose absorp-
tion across the small intestine blunting post-prandial blood 
glucose spikes could protect against development of type 
2 diabetes [36]. The ability of acarbose to inhibit carbo-
hydrate digestion is harnessed in the clinical setting [37] 
for diabetes management [38]. Some natural products and 
certain foods [13, 39–41] can act as acarbose-mimetics. As 
evidenced in healthy human volunteers, fruit pastes [19], 
coffee [42], green tea [43] and black tea [44] all modi-
fied some aspects of the glycaemic response. Given the 
wealth of evidence from animal studies, we decided to 
test oleuropein for its potential against developing type 
2 diabetes through inhibition of carbohydrate digestion 
and sugar absorption. We first employed relevant in vitro 
human enzymic systems, and then explored whether the 
observed effects following a single dose were sufficient to 
potentiate an in vivo effect in healthy volunteers (Fig. 10).
Starch and maltodextrin(s) are digested by α-amylase, 
followed by maltase. The latter can arise from sucrase-
isomaltase or maltase-glucoamylase, both located in the 
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Fig. 6  Effect of OLE or olives on postprandial blood glucose area 
under the curve during consumption of carbohydrates. Time depend-
ence of blood glucose after consumption of control (black circle; with 
solid line) and test (black triangle; with dotted line) meals. a Study 
1: double-blinded, randomised, crossover, placebo controlled in 24 
healthy volunteers consuming bread (109  g containing 50  g carbo-
hydrate) with OLE in capsules (500  mg, equivalent to 100  mg ole-
uropein). b Study 2: double-blinded, randomised, crossover, placebo 
controlled in 24 healthy volunteers consuming white bread (109  g 
containing 50  g carbohydrate) with OLE in capsules (2 × 500  mg, 
equivalent to 200 mg oleuropein). c Study 3: randomised, crossover, 
controlled study in 16 healthy volunteers consuming white bread 
(109  g containing 50  g carbohydrate) with 200  ml water with and 
without olives (100  g Kalamata olives containing 35  g oleuropein). 
d Study 4: randomised, crossover, controlled study on 10 healthy vol-
unteers consuming white bread (109 g containing 50 g carbohydrate) 
with 200  ml water (control) or containing 125  mg dissolved OLE 
(50  mg oleuropein). e Study 5: randomised, crossover, controlled 
study in 10 volunteers consuming wholemeal bread (132 g containing 
50 g carbohydrate) with 200 ml water (control) or containing 125 mg 
dissolved OLE (50 mg oleuropein). For additional details, see Table 2
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enterocyte brush border. Sucrose is digested only by the 
sucrase subunit of sucrase-isomaltase. The resulting sug-
ars are absorbed by transport across the enterocytes into 
the blood stream by glucose transporters, predominantly 
GLUT2 and SGLT1 in the intestine, or by fructose transport-
ers, mainly GLUT2 and GLUT5 (Fig. 10). We initially tested 
these sites for potential inhibition by OLE in vitro. Inhibition 
of human salivary α-amylase by OLE was relatively weak 
compared to acarbose and EGCG [21]. Inhibition of human 
and rat maltase activities by OLE were more potent than 
inhibition of α-amylase. OLE significantly inhibited trans-
port of glucose by GLUT2 in both differentiated Caco-2/
TC7 cell monolayers and into Xenopus oocytes express-
ing the human transporter. When the effectiveness of these 
in vitro results to reflect post prandial sugar metabolism in 
volunteers in vivo was tested, there was no effect following 
Fig. 7  Effect of OLE on 
postprandial blood glucose 
area under the curve during 
consumption of sugars. Time 
dependence of blood glucose 
after consumption of control 
(black circle; with solid line) 
and test (black triangle; with 
dotted line) meals. a Study 
6: randomised, crossover, 
controlled study on 10 healthy 
volunteers consuming glucose 
(50 g) with 200 ml water 
(control) or containing 125 mg 
dissolved OLE (50 mg oleuro-
pein). b Study 7: randomised, 
crossover, controlled study on 
10 healthy volunteers consum-
ing sucrose (50 g) with 200 ml 
water (control) or containing 
125 mg dissolved OLE (50 mg 
oleuropein). c Study 8: ran-
domised, crossover, controlled 
study on 10 healthy volunteers 
consuming sucrose (25 g) 
with 250 ml water (control) or 
containing 400 mg dissolved 
OLE (160 mg oleuropein). For 
additional details, see Table 3
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Fig. 8  Inter-individual differences in responses to sucrose and ole-
uropein. Randomised, crossover, controlled study on 10 healthy vol-
unteers consuming sucrose (25 g) with 250 ml water (control) (a) or 
250 ml water containing 400 mg dissolved OLE (160 mg oleuropein) 
(b), indicating changes in IAUC for each volunteer by linked data 
points from control to treatment, with mean of all data shown as dot-
ted line
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consumption of several different forms and doses up to 
160 mg of OLE with bread (white or wholemeal), indicat-
ing that the efficacy of OLE on α-amylase is not sufficient 
to inhibit bread digestion. However, the combined action 
of OLE on sucrase and on glucose transport is sufficient to 
produce an attenuation of sucrose digestion and on appear-
ance of glucose in the blood, but only at the lower dose of 
sucrose and higher dose of OLE.
Our in vitro data predict that oleuropein would not be 
modified in the small intestine, but could be absorbed or 
reach the colon intact where it would be metabolised by 
gut microbiota. This metabolism involves deglycosylation 
(Fig. 1) and conversion to lower molecular weight phenolics 
such as hydroxytyrosol [45, 46].
Since the effects reported here on carbohydrate digestion 
and sugar absorption are modest, it is likely that the dietary 
anti-diabetic effect of oleuropein is not through modulation 
of post prandial sugar metabolism. Instead, beneficial bio-
activities could be prompted by the modest absorption of 
intact oleuropein, or by the well absorbed lower molecular 
weight phenolics such as hydroxytyrosol, produced from gut 
microbiota-catalysed catabolism of oleuropein [47]. Such a 
hypothesis underlines the potential of gut microbial metabo-
lism to indirectly affect metabolic health and warrants fur-
ther research. The effects on sugar absorption reported here 
could be exploited through the design of supplements or 
functional foods [48] but it is unlikely they can account for 
the anti-diabetic effects of oleuropein [49], as naturally pre-
sent in olives and olive oil [1] from the diet.
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Fig. 9  Summary of IAUC and peak blood glucose from interven-
tion studies. Studies are numbered 1–9, and full details are given in 
Table 2
Fig. 10  Mechanism of action 
of oleuropein on sucrose 
hydrolysis and subsequent sugar 
transport. Digestion of starch, 
maltose and sucrose in the gut 
lumen and transport of glucose 
across the intestinal barrier. The 
arrows indicate the sites where 
oleuropein exhibits inhibition 
according to our data
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